SynthesisFrontiers in immunology2026
Network meta-analysis of novel diagnostic biomarkers for rheumatoid arthritis: comparative performance of anti-CarP, anti-MCV, and emerging markers.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Rheumatoid arthritis (RA) diagnosis remains challenging due to the limitations of conventional biomarkers. This network meta-analysis (NMA) aimed to compare the diagnostic performance of seven novel biomarkers for RA. Methods: We systematically searched EMBASE, PubMed, and Cochrane databases, identifying 1,713 records. Twelve studies met inclusion criteria. Diagnostic accuracy metrics (sensitivity, specificity, log diagnostic odds ratio [lnDOR]) were extracted. A frequentist NMA was performed using the netmeta package in R, with biomarkers ranked via P-scores against the ACR/EULAR RA criteria. Heterogeneity, transitivity, and publication bias were assessed. Results: Anti-carbamylated protein (Anti-CarP) antibody showed the highest diagnostic efficacy (P-score = 0.80; sensitivity 62 - 64%, specificity 89%), followed by anti-mutated citrullinated vimentin (Anti-MCV; P-score = 0.69). miR- 146a and power Doppler ultrasound (PDUS) demonstrated moderate performance (P-scores 0.46 and 0.45), while 14-3-3 η protein (P-score = 0.26) and its combination with ACPA (P-score = 0.07) ranked lowest. The network exhibited a star-shaped geometry with no significant inconsistency or publication bias (Egger 's test p = 0.52). Conclusion: Anti-CarP and Anti-MCV are the most promising diagnostic biomarkers for RA, Anti-CarP and Anti-MCV are the most promising diagnostic biomarkers for RA. Their potential utility in seronegative or early-stage RA warrants further investigation. The limited performance of 14-3-3 η challenges prior assumptions about its utility. Standardized thresholds and direct comparisons are needed for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.